Biotech Values

[genisi]

On Tysabri sales - they said units grew by 6% year-over-year in the U.S. but number of new patients was somewhat lower than last quarter. On the JCV immunoassay, they need the data from the ongoing STRATIFY studies to get the test approved. They are planning to submit labeling changes by the first quarter of next year.